US Edition
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
- Mabwell announced multiple clinical data presentations of novel antibody-drug conjugates at the 2025 ASCO Annual Meeting in Shanghai.
- These presentations follow phase I/II studies investigating 9MW2821, 7MW3711, and 9MW2921 targeting urothelial carcinoma, solid tumors, and advanced cancers respectively.
- The 9MW2821 oral presentation reports an 87.5% objective response rate and 92.5% disease control rate in 40 previously untreated urothelial carcinoma patients treated with 9MW2821 and Toripalimab.
- 7MW3711 showed a 36.0% ORR and 96.0% DCR among 25 lung cancer patients at doses of 4.5 mg/kg or greater, with no dose-limiting toxicity observed and maximum tolerated dose unreached.
- These results support Mabwell’s continued clinical development and regulatory designations, including Breakthrough Therapy and Fast Track, while manufacturing bases comply with international GMP standards.
Insights by Ground AI
Does this summary seem wrong?
12 Articles
12 Articles
All
Left
1
Center
2
Right
2
thepilotnews.com+11 Reposted by 11 other sources
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clinical study…
·Plymouth, United States
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left1Leaning Right2Center2Last UpdatedBias Distribution40% Center, 40% Right
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
40% Right
L 20%
C 40%
R 40%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
